Immediate Impact

3 by Nobel laureates 54 standout
Sub-graph 1 of 23

Citing Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
2 intermediate papers

Works of Mélanie Laporte being referenced

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer
2019

Author Peers

Author Last Decade Papers Cites
Mélanie Laporte 32 93 73 109 97 9 299
Mona Ahmed 27 45 33 126 179 9 322
Tania B. Porras 42 111 36 135 89 16 287
Basira Najafzadeh 69 78 35 116 170 10 325
Malin Berglund 30 26 35 128 124 15 300
Tingxuan Gu 33 41 52 84 149 14 258
Kwok-Wah Chan 34 36 32 62 150 9 285
Silvia Mezzalira 30 39 20 72 54 8 201
Gongyu Tang 36 91 58 40 220 9 291
Stephen Beil 23 26 93 45 102 6 292
Dario Lipari 15 36 79 49 50 9 243

All Works

Loading papers...

Rankless by CCL
2026